跳至主要内容
临床试验/ACTRN12620001213932
ACTRN12620001213932尚未招募未知

Evaluation of the Safety and Effectiveness of a Percutaneously Created Interatrial Shunt on Heart Failure Symptoms in Patients with Chronic Heart Failure and Preserved or Mid-Range Left Ventricular Ejection Fraction

Alleviant Medical Inc.0 个研究点目标入组 30 人开始时间: 2020年11月16日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
40 Years 至 o limit(—)
性别
All

入选标准

  • Candidates for the study must meet all of the following inclusion criteria at
  • 1. Documented history of NYHA Class II, Class III or ambulatory Class IV at the screening visit.
  • 2. History of at least one hospitalization for treatment of heart failure within the past 12 months.
  • 3. LVEF greater than or equal to 40% as measured by the study-specific transthoracic echocardiography.
  • 4. Echocardiographic evidence of diastolic dysfunction documented by one or more of the following as measured by the study-specific transthoracic echocardiography protocol performed during screening:
  • - LA diameter greater than 4 cm
  • - LA volume index greater than 28 mL
  • - Lateral e’ less than 10 cm/s
  • - Septal e’ less than 8 cm/s
  • - Lateral E/e’ greater than 10
  • - Septal E/e’ greater than 15
  • 5. Elevated left atrial pressure WITH a gradient compared to right atrial pressure (RAP) documented by:
  • (1) end-expiratory PCWP at peak supine cycle ergometer exercise greater than or equa. to 25 mmHg AND
  • (2) PCWP greater than RAP by greater than or equal to 5 mmHg, OR greater than or equal to 10 mmHg increase of end-expiratory PCWP at peak supine cycle ergometer exercise compared to resting PCWP AND PCWP greater than RAP by greater than or equal to 5 mmHg.

排除标准

  • Candidates for the study must be free of all of the following exclusion
  • criteria at screening:
  • 1. Presence of advanced heart failure defined as one or more of the following:
  • - ACC/AHA/ESC Stage D heart failure, non-ambulatory NYHA Class IV HF.
  • - Cardiac index less than 2.0 L/min/m2.
  • - Patient is on the cardiac transplant waiting list.
  • - Inotropic infusion (continuous or intermittent) for EF less than 40% within the past 6 months.
  • 2. Presence of moderate or worse valve disease, defined as one or more of the following:
  • - Moderate or worse mitral valve regurgitation or moderate or worse mitral stenosis.
  • - Moderate or worse tricuspid valve regurgitation.
  • - Moderate or worse aortic valve disease defined as moderate or worse AS or AI.
  • 3. . Presence of chronic pulmonary disease defined by one or more of the following:
  • - Requirement for continuous home oxygen use.
  • - Hospitalization within the past 12 months for treatment of pulmonary disease.
  • - Significant chronic pulmonary disease defined as FEV1 less than 50%.
  • 4. Documented as currently requiring dialysis or estimated GFR less than 25ml/min/1.73m2
  • 5. 6-minute walk distance less than 50 m or greater than 450 m performed during screening.
  • 6. Documented atrial fibrillation with ventricular rate greater than 100 BPM at screening.
  • 7. Presence of moderate or worse right heart dysfunction OR RV dysfunction defined as TAPSE less than 14 mm or RVFAC less than or equal to 30%
  • 8. Presence of pulmonary hypertension with PASP greater than or equal to 70 mmHg OR PVR greater than 4 Wood units.
  • 9. Presence of anatomic anomaly that precludes creation of interatrial shunt (including patent foramen ovale, atrial septal defect, target septal thickness greater than 3 mm)
  • 10. SBP greater than 170 mmHg at screening.
  • 11. Documented left ventricular end diastolic diameter greater than 6 cm.

研究者

相似试验